Scholars Central

Conference abstractPublished 2 Nov 2017

Bio-fabrication and evaluation of alginate chitosan microcapsules of Insulin secreting β TC-6 cells in the treatment of Type 1 diabetes mellitus

Authors: Amit Bansal, Sucheta D’Sa, Martin J D’Souza

Mercer University, USA; Charles River Laboratories, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Type 1 diabetes mellitus (T1DM) is a disease, characterized by lack of pancreatic islet function. Whole tissue transplantation appears to be viable alternative in the management of T1DM due to limitation of exogenous insulin therapy. This study aims at fabrication and evaluation of alginate-chitosan microcapsule encapsulated insulin secreting Ã?² TC-6 cells using specialized spraying nozzle. Microcapsules encapsulated with Ã?² TC-6 cells were fabricated using novel spraying device producing uniform spherical microcapsules. Microcapsules were characterized for permeability using molecular weight markers, stability, and cell viability using live dead staining kit. Microencapsulated Ã?² TC-6 cells were transplanted intra-peritoneally in streptozotocin (STZ) induced diabetic mice and monitored for decrease in blood glucose level and immune acceptance. Spherical microcapsules with diameter in the range of 250-350 Ã?µm were prepared at an air flow rate of 250 L/hr. Microencapsulated Ã?² TC-6 cells in alginate capsules demonstrated prolonged viability. Mice in microencapsulated cells group received microencapsulated Ã?² TC-6 cells maintains normoglycemia for 35Ã?±5 days before rejection. However, mice in unencapsulated cells group received naked Ã?² TC-6 cells rejected graft within 1 or 2 days and exhibit both cellular and humoral immune responses. CD4 T-cells mediated Th2 response i.e. humoral response was predominant in microencapsulated Ã?² TC-6 cells group and that was further confirmed from elevated levels of CD45R. Microcapsules produced by specialized nozzle were reproducible with narrow size distribution and in addition provides flexibility in producing different sized capsules. Our findings for in-vivo study revealed that transplantation of microencapsulated Ã?² TC-6 cells may be a viable alternative in the management of T1DM with greater immune acceptance.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Clinical and Cellular Immunology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical and Cellular Immunology
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Amit Bansal”
  • BylineArticles whose byline prints “Sucheta D’Sa”
  • BylineArticles whose byline prints “Martin J D’Souza”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels